10-KPeriod: FY2020

DOVER Corp Annual Report, Year Ended Dec 31, 2020

Filed February 12, 2021For Securities:DOV

Summary

Dover Corporation (DOV) reported its 2020 annual results, facing a revenue decline of 6.3% to $6.7 billion, largely due to the impact of the COVID-19 pandemic on its various end markets. Despite the revenue dip, the company demonstrated resilience with an improvement in gross profit margin to 37.0% and a significant increase in free cash flow to $939.1 million. The company executed several acquisitions in 2020, totaling $335.8 million, to strengthen its Imaging & Identification, Fueling Solutions, Engineered Products, and Pumps & Process Solutions segments, indicating a continued focus on strategic portfolio enhancement. Dover also managed its capital effectively, repurchasing $106.3 million in stock and increasing its dividend, underscoring a commitment to shareholder returns. The company operates through five segments: Engineered Products, Fueling Solutions, Imaging & Identification, Pumps & Process Solutions, and Refrigeration & Food Equipment. While most segments experienced revenue declines due to COVID-19, the company noted sequential improvements in activity towards the end of the year and expressed optimism for continued financial performance improvement in 2021, supported by a stronger backlog. Management remains focused on driving organic growth, improving profitability, and allocating capital efficiently, with a clear strategy to acquire value-creating businesses and return capital to shareholders.

Financial Statements
Beta

Key Highlights

  • 1Dover Corporation's revenue for 2020 decreased by 6.3% to $6.7 billion, primarily impacted by the COVID-19 pandemic across its end markets.
  • 2Despite revenue challenges, gross profit margin improved to 37.0% due to productivity initiatives and cost containment actions.
  • 3Free cash flow significantly increased to $939.1 million, demonstrating strong operational cash generation.
  • 4The company completed six acquisitions in 2020 for a total of $335.8 million, bolstering specific segments like Imaging & Identification and Fueling Solutions.
  • 5Dover continued its shareholder return strategy, repurchasing $106.3 million of its stock and increasing its dividend for the 65th consecutive year.
  • 6Backlog increased to $1.8 billion by year-end 2020, signaling positive order trends and expected improvement in financial results for 2021.
  • 7The company maintained effective controls over financial reporting and experienced no material changes in internal controls during the year.

Frequently Asked Questions

The COVID-19 pandemic had a significant adverse impact on Dover's revenue, leading to a 6.3% decrease to $6.7 billion. Several end-markets experienced reduced demand and operational disruptions. However, the company implemented cost savings measures and saw sequential improvements in activity in most markets towards the latter half of the year.

Dover actively managed its capital by repurchasing $106.3 million of its common stock. The company also demonstrated its commitment to shareholder returns by increasing its dividend for the 65th consecutive year. Financially, free cash flow generation was robust, reaching $939.1 million, which supports these capital allocation strategies.

Dover's strategy is focused on three key tenets: achieving organic sales growth above GDP (3-5% annually), improving returns on capital and margins through operational enhancements and digital investments, and generating strong free cash flow. The company also actively manages its portfolio through disciplined acquisitions and opportunistic divestitures.

Most segments faced revenue declines due to COVID-19. However, the company noted resilience in its Aerospace & Defense business within Engineered Products. While the Digital Textile Printing business in Imaging & Identification was materially impacted, the marking and coding business showed solid demand for consumables and a strong second-half recovery in equipment sales. Pumps & Process Solutions saw strong performance in biopharma and hygienic markets, offsetting weakness in other areas.